Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (effect-RLS study)

Movement Disorders

Volumn 22, Issue 2, 2007, Pages 213-219

  Oertel, Wolfgang H ^a   Stiasny Kolster, Karin ^a   Bergtholdt, Bettina ^b   Hallström, Yngve ^c   Albo, Jaan ^d   Leissner, Lena ^e   Schindler, Thomas ^f   Koester, Juergen ^f   Reess, Juergen ^f  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Emovis GmbH   (Germany)

^c Neuro Center   (Sweden)

^d Läkarhuset i Vällingby   (Sweden)

^e Neurologiska Kliniken   (Sweden)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Clinical trial; Dopamine agonist; Pramipexole; Restless legs syndrome

Indexed keywords

BENZODIAZEPINE; DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; PRAMIPEXOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DEMOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 33847767130     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21261     Document Type: Article

References (14)

1. Walters AS, for the International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Disord 1995;10:634-642.
2. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J, for the International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-119.
3. Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and morbidity in Augsburg elderly. Neurology 2000;54:1064-1068.
4. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-1292.
5. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52:938-943.
6. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000;7(Suppl. 1):27-31.
7. Walters AS, Le Brocq C, Dhar A, et al, for the International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-132.
8. Hening WA, Allen RP. Restless legs syndrome (RLS): the continuing development of diagnostic standards and severity measures. Sleep Med 2003;4:95-97.
9. National Institute of Mental Health (NIMH). Early clinical drug evaluation unit (ECDEU). clinical global impressions. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Revised ed. Rockville, MD: NIMH; 1976. p 216-222.
10. Kohnen R, Oertel WH, Stiasny-Kolster K, Benes H, Trenkwalder C. Severity rating of restless legs syndrome: review of ten years experience with the RLS-6 scales in clinical trials [abstract 0860.N]. In: Scientific highlights/abstracts of original investigations of the 17th annual meeting of the APSS, June 3-8, 2003, Chicago, Illinois. Sleep 2003;26(Suppl.):A342.
11. Wetter TC, Stiasny K, Winkelmann J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52:944-950.
12. Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004;63:2272-2279.
13. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al, for the Therapy with Ropinirole Efficacy and Tolerability in RLS 1 Study Group. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-97.
14. Stiasny-Kolster K, Kohnen R, Schollmayer E, Möller JC, Oertel WH, and the Rotigotine Sp 666 Study Group. Patch-application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004;19:1432-1438.